Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
VHH VE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH EV
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH EEE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH EE
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
aRBD-2-5
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/03/2021
S309
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
VHH W
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH V
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH U
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
VHH E
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/12/2021
Ferritin-NP-RBD
Potential treatment - pre-clinical evidence Experimental Vaccine Feb/12/2021
NBP11
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
Cilgavimab
Emergency use authorization Experimental Antiviral Jun/18/2022
LSNME/SW1
Potential treatment - pre-clinical evidence Experimental Vaccine Oct/01/2021
1-{3-[2-Hydroxy-3-(4-methylpiperidino)propoxy]phenoxy}-3-(4-methylpiperidino)-2-propanol
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
NBP10
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
Mesenchymal stem cells
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
VH-Fc ab8
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/29/2021
2-{3-[3-Chloro-5-(cyclopropylmethoxy)phenyl]-2-oxo[2H-[1,3'-bipyridine]]-5-yl}benzonitrile
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/22/2021
ABP18
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021